The marketing alliance between biopharmaceutical start-up Palatin and healthcare giant Mallinckrodt for Palatin’s radiolabeled infection imaging agent, LeuTech (SCAN 5/26/99), has become official. Under the terms of the agreement,
The marketing alliance between biopharmaceutical start-up Palatin and healthcare giant Mallinckrodt for Palatins radiolabeled infection imaging agent, LeuTech (SCAN 5/26/99), has become official. Under the terms of the agreement, Mallinckrodt paid Palatin a licensing fee of $500,000 and acquired 700,000 restricted unregistered shares of Palatin preferred stock for an additional $13 million. An extra $10 million in milestone payments will be paid to Palatin upon Food and Drug Administration approval of the first indication for LeuTech, and the attainment of certain sales goals following the commercial introduction of this product. St. Louis-based Mallinckrodt will also reimburse Palatin for 50% of all ongoing LeuTech development costs, while Palatin, which is based in Princeton, NJ, will manufacture LeuTech and receive a transfer price on each product unit and a royalty on net LeuTech sales.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.